Highlights

  • Adheris Health (ASX:AHE) is repositioning its Business around higher-margin digital patient-engagement products.
  • FY2026 Revenue declined materially, although the company achieved cashflow break-even in the final quarter.
  • The THRiV platform is becoming a larger part of the company's revenue mix and future pipeline.
  • Cost reduction, pharmaceutical customer renewals and the ongoing US litigation remain key factors to monitor.

Adheris Health (ASX:AHE) — the pharmacy-network technology company Australian investors knew for years as MedAdvisor before its December 2025 rebrand — is in the middle of one of the more difficult turnarounds on the ASX healthcare boards. FY2026 revenue nearly halved to $34.0 million from about $63 million a year earlier, driven by weaker pharmaceutical-customer renewals and reduced first-half bookings, yet the company still reached cashflow break-even in its final quarter and ended the year debt-free with $9.5 million in the bank.

The company is also contending with a US lawsuit from an IT services provider. Investors watching Adheris Health are essentially weighing whether a pivot toward higher-margin digital patient-engagement products can offset the structural decline in its legacy pharmacy-messaging business quickly enough to matter.

What Has Happened?

The company rebranded from MedAdvisor Limited (ASX:MDR) to Adheris Health Limited (ASX:AHE) effective 1 December 2025, following approval at its 2025 Annual General Meeting, a change management described as reflecting its focus on the THRiV platform and pharmacy-driven patient engagement across a US network of tens of thousands of pharmacies.

During FY2026, the company also completed a series of business disposals, including its ANZ operations, generating $30.2 million in total proceeds for the year and materially strengthening the balance sheet.

Operationally, the fourth quarter of FY2026 delivered a net operating cashflow inflow of $0.2 million, a sharp swing from a $4.7 million outflow in the prior quarter, aided by improved receivables management even as Operating Revenue fell 44.6% year-on-year to $5.6 million. Chief executive John Ciccio described the sales team as "laser focused" on rebuilding the pipeline heading into the next pharmaceutical budget cycle.

On 31 July 2026, the company disclosed that its US subsidiary, Adheris LLC, faces a lawsuit from IT provider Mindsprint, filed in the US District Court for the Southern District of New York, seeking at least US$2.3 million in damages over a Master Services Agreement Adheris terminated for cause in May and June 2026. Mindsprint alleges breach of contract; Adheris denies Liability and says it will "vigorously defend" the case, adding it does not expect the proceedings to affect operations and cannot yet quantify any financial impact.

Understanding the Business

Adheris Health (ASX:AHE) operates a US-based pharmacy-network technology and patient-engagement platform, historically monetised through pharmaceutical company-sponsored messaging and vaccine-reminder campaigns delivered at the point of dispensing, reaching tens of thousands of US pharmacies and an estimated 170 million Americans.

Its newer, higher-margin offering is the THRiV platform, which uses predictive modelling to target patient-engagement and awareness campaigns. The company cites patient therapy return rates of approximately 65%, average SMS click-through rates exceeding 24%, and an average awareness-program lift of around 11%.

The company holds business-associate relationships with nine of the top ten US pharmacy chains and describes pharmaceutical-industry partnerships averaging more than 15 years, underscoring a deeply entrenched distribution network even as the revenue generated through that network has come under pressure.

Financial and Operational Picture

For FY2026, ended 30 June 2026, Adheris Health reported revenue of $34.0 million, down 46% from approximately $63 million in FY2025, with Gross Profit falling 56% to $14.6 million as gross margins compressed by roughly nine percentage points.

The company ended the year with net cash of $9.5 million and no debt, supported by $30.2 million in disposal proceeds generated during the year, including the ANZ business sale.

Non-vaccine revenue rose to 83% of the FY2026 total, up from 54% in FY2025, while digital programs grew from about 6% of revenue in January 2026 to 15% by June 2026, with the THRiV platform said to represent roughly 60% of the company's calendar-2027 pipeline opportunity value.

Management is targeting FY2027 staff costs of around $18.2 million, down sharply from roughly $34 million in FY2025, as part of a broader cost-base reset.

Why This Matters

The scale of the FY2026 revenue decline — nearly halving in a single year — reflects both a weak pharmaceutical customer budget cycle and reduced first-half bookings, but the fact that Adheris still reached cashflow break-even and holds a debt-free, $9.5 million cash balance gives it runway to execute a genuine pivot rather than face an immediate funding crisis.

The shift in digital revenue mix, with THRiV moving from 6% to 15% of revenue within six months, is early but tangible evidence that the strategy of moving away from lower-margin Vaccine messaging toward higher-margin, technology-driven patient engagement is gaining some traction, even from a low base.

Industry Opportunity

Pharmaceutical manufacturers continue to seek scaled, compliant channels for reaching patients at the point of care, and pharmacy networks remain among the most trusted touchpoints for medication-adherence and disease-awareness campaigns within the US healthcare system.

As pharmaceutical Marketing budgets increasingly favour measurable, digitally delivered engagement over broad-based vaccine messaging, platforms such as THRiV — with established distribution across the majority of major US pharmacy chains — are positioned to capture a growing share of that spend, provided they can demonstrate Return on Investment at scale.

Potential Catalysts

Investors may be watching for continued growth in THRiV and digital revenue as a share of the overall mix through FY2027, a successful rebuild of the pharmaceutical customer pipeline that management has described as a near-term priority, and sustained cashflow break-even or better as the new financial year progresses.

These developments would help validate the cost-reset program already under way. A contained or favourable resolution of the Mindsprint litigation would also remove a lingering overhang.

Risks Investors Should Consider

The Mindsprint lawsuit, seeking at least US$2.3 million, is at an early stage, and its ultimate financial impact cannot yet be quantified by the company. Litigation costs and management distraction represent a near-term overhang regardless of the eventual outcome.

Continued dependence on pharmaceutical marketing budgets — already the direct cause of the FY2026 revenue decline — remains a material structural risk.

There is also execution risk in shifting a legacy vaccine-messaging business toward digital products fast enough to offset further declines in the base business. Management's own disclosure of reduced first-half bookings suggests visibility into near-term revenue recovery remains limited.

What to Watch Next

Key milestones include the FY2027 first-half results and confirmation of whether cashflow break-even is sustained, developments in the Mindsprint litigation, further disclosure on THRiV and digital revenue mix and pipeline conversion into calendar 2027, and any additional cost-reduction or portfolio-simplification announcements as the company completes its post-rebrand restructuring.